JP2015518827A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518827A5
JP2015518827A5 JP2015512727A JP2015512727A JP2015518827A5 JP 2015518827 A5 JP2015518827 A5 JP 2015518827A5 JP 2015512727 A JP2015512727 A JP 2015512727A JP 2015512727 A JP2015512727 A JP 2015512727A JP 2015518827 A5 JP2015518827 A5 JP 2015518827A5
Authority
JP
Japan
Prior art keywords
seq
sequence number
sequence
variable region
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015512727A
Other languages
English (en)
Japanese (ja)
Other versions
JP6441792B2 (ja
JP2015518827A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/040827 external-priority patent/WO2013173255A2/en
Publication of JP2015518827A publication Critical patent/JP2015518827A/ja
Publication of JP2015518827A5 publication Critical patent/JP2015518827A5/ja
Application granted granted Critical
Publication of JP6441792B2 publication Critical patent/JP6441792B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015512727A 2012-05-17 2013-05-13 Egfrに結合する抗原結合蛋白質 Expired - Fee Related JP6441792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648391P 2012-05-17 2012-05-17
US61/648,391 2012-05-17
PCT/US2013/040827 WO2013173255A2 (en) 2012-05-17 2013-05-13 Antigen binding proteins that bind egfr

Publications (3)

Publication Number Publication Date
JP2015518827A JP2015518827A (ja) 2015-07-06
JP2015518827A5 true JP2015518827A5 (https=) 2016-06-30
JP6441792B2 JP6441792B2 (ja) 2018-12-19

Family

ID=49581478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512727A Expired - Fee Related JP6441792B2 (ja) 2012-05-17 2013-05-13 Egfrに結合する抗原結合蛋白質

Country Status (7)

Country Link
US (1) US9944707B2 (https=)
EP (1) EP2850105A4 (https=)
JP (1) JP6441792B2 (https=)
CN (1) CN104918956A (https=)
CA (1) CA2872018A1 (https=)
HK (1) HK1208474A1 (https=)
WO (1) WO2013173255A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280442A4 (en) * 2015-04-08 2018-10-31 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd123
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
US11045547B2 (en) * 2015-12-16 2021-06-29 Merck Sharp & Dohme Corp. Anti-LAG3 antibodies and antigen-binding fragments
RU2757314C2 (ru) 2016-01-22 2021-10-13 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
ES2912903T3 (es) 2016-04-27 2022-05-30 Green Cross Corp Composición farmacéutica para inhibir la metástasis del cáncer, que comprende, como principio activo, un anticuerpo que se une específicamente al receptor del factor de crecimiento epidérmico
IL315266A (en) 2016-06-14 2024-10-01 Merck Sharp ַ& Dohme Llc Anti-coagulation factor xi antibodies
WO2020247290A1 (en) * 2019-06-04 2020-12-10 Academia Sinica Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
WO2021035096A1 (en) * 2019-08-20 2021-02-25 Kumquat Biosciences Inc. Compositions and methods for targeting cellular molecules
EP4347643A4 (en) * 2021-05-27 2025-09-17 Us Gov Veterans Affairs HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO STREPTOLYSIN O AND METHODS OF USE
EP4473018A2 (en) * 2022-02-04 2024-12-11 Vivasor, Inc. Antigen binding proteins that bind b7-h3

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT699237E (pt) * 1994-03-17 2003-07-31 Merck Patent Gmbh Fvs de cadeia anti-egfr e anticorpos anti-egfr
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ErbB2 항체 투여 치료 방법
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2450285C (en) * 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
CN101233155B (zh) * 2004-03-19 2013-06-19 英克隆有限责任公司 人抗表皮生长因子受体抗体
CA2560305C (en) 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
PL1871805T3 (pl) * 2005-02-07 2020-03-31 Roche Glycart Ag Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
DK1951759T3 (da) * 2005-11-12 2010-05-10 Lilly Co Eli Anti-EGFR-antistoffer
US8329421B2 (en) 2007-07-13 2012-12-11 Ventana Medical Systems, Inc. Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein
CN102164960A (zh) 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
EP2392323A4 (en) 2009-01-30 2012-09-26 Univ Kyoto INHIBITOR OF PROSTATE CANCER PROGRESSION AND METHOD OF INHIBITING PROGRESSION
CA2754646A1 (en) 2009-03-31 2010-10-07 Roche Glycart Ag Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
CA2777825A1 (en) 2009-10-28 2011-05-19 Abbott Biotherapeutics Corp. Anti-egfr antibodies and their uses
EP2502936B1 (en) 2009-11-18 2016-01-06 Tohoku University Highly-functional mutant of humanized anti-egfr antibody variable region
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
EA201390472A1 (ru) 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
TWI443108B (zh) 2011-12-28 2014-07-01 Ind Tech Res Inst 抗人類表皮生長因子受體抗體及其應用

Similar Documents

Publication Publication Date Title
JP6829330B2 (ja) Pd−l1に結合する抗原結合蛋白質
JP6997743B2 (ja) Pd-1に結合する抗原結合蛋白質
US11919952B2 (en) Antigen binding proteins that bind PD-L1
US12084503B2 (en) Fully human antibodies that bind to vascular endothelial growth factor receptor 2 (VEGFR2) and methods of use thereof for treatment
JP6441792B2 (ja) Egfrに結合する抗原結合蛋白質
JP2015518827A5 (https=)
CN105120890B (zh) 与ErbB3结合的抗原结合蛋白
JP2015520172A (ja) Dll−4に結合する抗原結合蛋白質
CN104411332B (zh) 与vegfr2结合的全人抗体
JP6388576B2 (ja) Igf1rに結合する抗原結合タンパク質